Alessia Covre
Overview
Explore the profile of Alessia Covre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lofiego M, Tufano R, Bello E, Solmonese L, Marzani F, Piazzini F, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):58.
PMID: 39966970
Background: Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1 has recently become the new first-line standard of care therapy of pleural mesothelioma (PM) patients, with a significant improvement of...
2.
Montico B, Giurato G, Guerrieri R, Colizzi F, Salvati A, Nassa G, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):53.
PMID: 39953610
Background: About 50% of cutaneous melanoma (CM) harbors the activating BRAF mutation which exerts most of the oncogenic effects through the MAPK signaling pathway. In the last years, a number...
3.
Di Giacomo A, Chiarion-Sileni V, Del Vecchio M, Ferrucci P, Guida M, Quaglino P, et al.
Eur J Cancer
. 2024 Mar;
202:113981.
PMID: 38461074
No abstract available.
4.
Lofiego M, Piazzini F, Caruso F, Marzani F, Solmonese L, Bello E, et al.
J Transl Med
. 2024 Mar;
22(1):223.
PMID: 38429759
Background: Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, that is refractory to standard treatment and to immunotherapy with immune-checkpoint inhibitors (ICI). Noteworthy, melanoma brain metastases (MM-BM), that...
5.
Splendiani E, Besharat Z, Covre A, Maio M, Di Giacomo A, Ferretti E
Pharmacol Ther
. 2024 Feb;
256:108613.
PMID: 38367867
Melanoma is the most aggressive form of skin cancer, representing approximately 4% of all cutaneous neoplasms and accounting for up to 80% of deaths. Advanced stages of melanoma involve metastatic...
6.
Di Giacomo A, Chiarion-Sileni V, Del Vecchio M, Ferrucci P, Guida M, Quaglino P, et al.
Eur J Cancer
. 2024 Jan;
199:113531.
PMID: 38271746
Background: The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab. Methods:...
7.
Calabro L, Bronte G, Grosso F, Cerbone L, Delmonte A, Nicolini F, et al.
Front Immunol
. 2024 Jan;
14:1333661.
PMID: 38259475
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of...
8.
Noviello T, Di Giacomo A, Caruso F, Covre A, Mortarini R, Scala G, et al.
Nat Commun
. 2023 Sep;
14(1):5914.
PMID: 37739939
Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma...
9.
Anichini A, Molla A, Nicolini G, Perotti V, Sgambelluri F, Covre A, et al.
J Exp Clin Cancer Res
. 2022 Nov;
41(1):325.
PMID: 36397155
Background: Improvement of efficacy of immune checkpoint blockade (ICB) remains a major clinical goal. Association of ICB with immunomodulatory epigenetic drugs is an option. However, epigenetic inhibitors show a heterogeneous...
10.
Sabato C, Noviello T, Covre A, Coral S, Caruso F, Besharat Z, et al.
J Transl Med
. 2022 Oct;
20(1):469.
PMID: 36243798
Background: Melanoma is the deadliest form of skin cancer and metastatic disease is associated with a significant survival rate drop. There is an urgent need for consistent tumor biomarkers to...